https://www.selleckchem.com/products/brusatol.html
Objective To compare relapse rates and healthcare costs in MS patients treated with Glatopa 20mg (generic glatiramer acetate) versus Copaxone 20mg in a US managed care population.Methods A retrospective claims study was conducted using the HealthCore Integrated Research Database. Patients with ≥1 Glatopa or Copaxone claim between 04/01/2015 (Glatopa) or 01/01/2013 (Copaxone) and 04/30/2018 were included. Patients with prior Copaxone 40mg use or less then 1 year continuous health plan enrollment were excluded. Patients who switched from
Like
Comment
Share
